Trial Profile
A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg versus Tegeline in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Sponsors LFB Biotechnologies
- 04 Apr 2022 Status changed from recruiting to completed.
- 31 Mar 2015 New trial record